These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33394692)

  • 21. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
    Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
    J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
    [No Abstract]   [Full Text] [Related]  

  • 22. A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.
    Srivastava RAK
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
    Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility gene card for: hyperlipoproteinemia, TYPE II.
    Kassner U; Wühle-Demuth M; Missala I; Humphries SE; Steinhagen-Thiessen E; Demuth I
    Eur J Hum Genet; 2014 Jul; 22(7):. PubMed ID: 24253857
    [No Abstract]   [Full Text] [Related]  

  • 25. Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia.
    Rieck L; Bardey F; Grenkowitz T; Bertram L; Helmuth J; Mischung C; Spranger J; Steinhagen-Thiessen E; Bobbert T; Kassner U; Demuth I
    Clin Genet; 2020 Nov; 98(5):457-467. PubMed ID: 32770674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current status of familial hypercholesterolemia in Chinese populations.
    Tomlinson B; Hu M; Chow E
    Curr Opin Lipidol; 2019 Apr; 30(2):94-100. PubMed ID: 30649024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia.
    Climent E; Pérez-Calahorra S; Marco-Benedí V; Plana N; Sánchez R; Ros E; Ascaso JF; Puzo J; Almagro F; Lahoz C; Civeira F; Pedro-Botet J
    Sci Rep; 2017 Jul; 7(1):5596. PubMed ID: 28717233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Durst R; Ibe UK; Shpitzen S; Schurr D; Eliav O; Futema M; Whittall R; Szalat A; Meiner V; Knobler H; Gavish D; Henkin Y; Ellis A; Rubinstein A; Harats D; Bitzur R; Hershkovitz B; Humphries SE; Leitersdorf E
    Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
    Aljenedil S; Ruel I; Watters K; Genest J
    J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Bajaj A; Cuchel M
    Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of familial hypercholesterolemia-associated genes on the phenotype of premature myocardial infarction.
    Lee C; Cui Y; Song J; Li S; Zhang F; Wu M; Li L; Hu D; Chen H
    Lipids Health Dis; 2019 Apr; 18(1):95. PubMed ID: 30971288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and treatment of familial hypercholesterolaemia.
    Hovingh GK; Davidson MH; Kastelein JJ; O'Connor AM
    Eur Heart J; 2013 Apr; 34(13):962-71. PubMed ID: 23416791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
    Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic testing of familial hypercholesterolemia in a real clinical setting.
    Vohnout B; Gabcova D; Huckova M; Klimes I; Gasperikova D; Raslova K
    Wien Klin Wochenschr; 2016 Dec; 128(23-24):916-921. PubMed ID: 27542166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.
    Defesche JC; Stefanutti C; Langslet G; Hopkins PN; Seiz W; Baccara-Dinet MT; Hamon SC; Banerjee P; Kastelein JJP
    J Clin Lipidol; 2017; 11(6):1338-1346.e7. PubMed ID: 28964736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.
    Baum SJ; Brown AS
    Rev Cardiovasc Med; 2018; 19(S1):S25-S30. PubMed ID: 30207555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.